Dr. Darpan Pandya is an Associate Research Scientist in the Department of Radiology at the University of Iowa’s Carver College of Medicine and is supported by research funding that is administered by the National Institutes of Health, Melanoma Research Alliance and the North Carolina Biotechnology Center. He has 13 years of experience in the fields of cancer imaging, targeted radiotherapy, complex ligand synthesis, metal ion coordination chemistry and radiometal-chelate chemistry. These research efforts in radiopharmaceutical development have resulted in 8 patents and more than 25 journal publications, which have been cited more than 470 times in peer reviewed journals. Recently, He co-developed [²²⁵Ac]Ac-DOTA-MC1RL, which is a targeted alpha particle therapy for ocular and cutaneous melanomas that will enter a first-in-human clinical trial in April 2020. Currently, He is developing novel radiopharmaceuticals for the imaging and therapy of cancer using ⁶⁴Cu, ⁸⁹Zr and ²²⁵Ac, respectively. In addition to his research endeavors, He serves as a manuscript reviewer for several prestigious journals including Bioconjugate Chemistry and the Journal of Nuclear Medicine.  He also serves as an abstract reviewer for the World Molecular Imaging Congress and the Society of Nuclear Medicine and Molecular Imaging.